Bisphosphonates in the Treatment of Osteoporosis

被引：54
|
作者：
Diab, Dima L. [1 ]
Watts, Nelson B. [2 ]
机构：
[1] Univ Cincinnati, Cincinnati VA Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Cincinnati, OH 45267 USA
[2] Mercy Hlth Osteoporosis & Bone Hlth Serv, Cincinnati, OH 45236 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2012年 / 41卷 / 03期
关键词：
Bisphosphonates; Osteoporosis; Long-term safety; Osteonecrosis of the jaw; Atypical femur fractures; Atrial fibrillation; Esophageal cancer; Drug holidays; SUPPRESSED BONE TURNOVER; FEMORAL-SHAFT FRACTURES; ORAL BISPHOSPHONATES; ATRIAL-FIBRILLATION; ZOLEDRONIC ACID; BREAST-CANCER; POSTMENOPAUSAL OSTEOPOROSIS; AVASCULAR NECROSIS; INSUFFICIENCY FRACTURES; ESOPHAGEAL CANCER;
D O I：
10.1016/j.ecl.2012.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Bisphosphonates are widely used in the treatment of osteoporosis to reduce fracture risk. Because of their long retention time in bone and uncommon side effects, questions have been raised about the optimal duration of therapy. Potential side effects appear to be rare and may not be causally related. Although there is no strong science to guide "drug holidays," there appears to be some lingering antifracture benefit when treatment is stopped, so some time off treatment should be offered to most patients on long-term bisphosphonate therapy. For most patients with osteoporosis, the benefits of treatment outweigh the risks.
引用
收藏
页码：487 / +
页数：21
相关论文
共 50 条
12345